CytomX Therapeutics, Inc.
CTMX
$3.79
-$0.09-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -240.44% | -348.06% | 97.64% | 70.58% | 2,155.20% |
| Total Depreciation and Amortization | 23.49% | -68.76% | -24.40% | -17.56% | -15.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.79% | 4.10% | 47.42% | 156.57% | 75.19% |
| Change in Net Operating Assets | 101.05% | 88.38% | -21.18% | -15.14% | -68.69% |
| Cash from Operations | -16.75% | 24.99% | 19.42% | 19.21% | 9.36% |
| Capital Expenditure | -151.25% | 768.42% | 71.88% | -3.48% | 69.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -193.45% | -98.28% | -453.26% | -31.74% | 15.86% |
| Cash from Investing | -195.27% | -97.58% | -454.96% | -31.83% | 17.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 640.02% | -- | 1,734.67% | -- | 821.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 640.02% | -- | 1,734.67% | -- | 821.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -732.77% | -480.09% | -79.65% | -49.76% | 71.49% |